亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

作者
Jeremy S. Abramson,Matthew Ku,Christopher P. Fox,Huiqiang Huang,Huilai Zhang,William Townsend,Dok Hyun Yoon,Won-Seog Kim,Haifaa Abdulhaq,Charles Herbaux,Jan Maciej Zaucha,Hung Chang,Estefania Mulvihill,Murali Kesavan,Martine Kallemeijn,Rogachikova Ta,Voleak Choeurng,Alessia Bottos,Linda Lundberg,Gareth P. Gregory
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 5519-5519
标识
DOI:10.1182/blood-2025-5519
摘要

Abstract Background Glofitamab, a CD20xCD3 bispecific antibody, when combined with GemOx (Glofit-GemOx) has demonstrated significant improvements in overall survival (OS), progression-free survival (PFS), and complete response (CR) rate in patients with R/R DLBCL who are ineligible for autologous stem cell transplant (ASCT; Abramson et al. Lancet 2024). We report updated efficacy and safety of Glofit-GemOx versus R-GemOx, with 3 years of follow-up, in patients with R/R DLBCL after ≥1 prior line of therapy (LOT) from the global Phase III STARGLO trial (NCT04408638). Methods Patients were randomized 2:1 to either Glofit-GemOx (8 cycles plus 4 cycles glofitamab monotherapy) or R-GemOx (8 cycles) and stratified by number of prior LOT (1 vs ≥2) and refractoriness to last therapy. Following obinutuzumab pretreatment, glofitamab was given in Cycle 1 as weekly step-up doses (2.5/10mg), then 30mg target dose every 21 days from Cycle 2 Day 1. Patients enrolling after 1 prior LOT had to be ineligible for ASCT. The primary endpoint was OS. Secondary endpoints included independent review committee (IRC)-assessed PFS and CR rate. Landmark analyses of patients in CR at end of treatment (EOT) were conducted. Results Of the 274 (Glofit-GemOx, n=183; R-GemOx, n=91) patients with R/R DLBCL enrolled (intent-to-treat [ITT] population), 172 (62.8%) had 1 prior LOT, 102 (37.2%) had ≥2 prior LOT, 153 (55.8%) had primary refractory disease, and 166 (60.6%) were refractory to their last therapy. Of the patients with 1 prior LOT, 95 (55.2%) were primary refractory. Baseline characteristics were unchanged and balanced across arms. After 3 years of OS follow up (data cut-off: May 1, 2025; median follow-up: 35.1 months), Glofit-GemOx continued to demonstrate favorable outcomes versus R-GemOx in the ITT: median OS, 25.5 vs 12.5 months (hazard ratio [HR] 0.60, 95% confidence interval [CI]: 0.43–0.83); IRC-assessed median PFS, 14.4 vs 3.3 months (HR 0.41, 95% CI: 0.29–0.57); and CR rate, 58.5 vs 25.3%, respectively. The 36-month OS estimates were 47.1% for Glofit-GemOx and 27.4% for R-GemOx, and the 30-month PFS estimates were 38.1% for Glofit-GemOx and 15.2% for R-GemOx. Among patients who achieved CR at any time point (Glofit-GemOx, n=107; R-GemOx, n=23; median follow-up: 24.0 months), median duration of CR was not reached (95% CI: 27.2–not estimable [NE]) with Glofit-GemOx and was 24.2 months (95% CI: 6.9–NE) with R-GemOx. Amongst Glofit-GemOx-treated patients with a CR at EOT, the 24-month OS and PFS rates were 79.4% and 74.2%, respectively. A more pronounced efficacy benefit was observed for Glofit-GemOx versus R-GemOx in patients with 1 prior LOT: median OS, NE vs 14.4 months (HR 0.58, 95% CI: 0.38–0.89); median PFS, 20.4 vs 5.5 months (HR 0.49, 95% CI: 0.31–0.78); and CR rate (63.5 vs 28.1%). The 36-month OS estimates for these patients were 54.6% with Glofit-GemOx and 30.8% with R-GemOx, and the 30-month PFS estimates were 41.5% for Glofit-GemOx and 26.3 for R-GemOx. The safety profile was unchanged with extended follow up: no new signals were identified, and no evidence of cumulative toxicity or new long-term adverse events (AEs) were observed. In glofitamab-exposed patients, cytokine release syndrome (CRS) remained the most common AE (44.8%: Grade 1, 32.0%; Grade 2, 10.5%; Grade 3, 2.3%) and events consistent with immune effector cell-associated neurotoxicity syndrome occurred in 4 patients (all concurrent with CRS; most Grade 1–2 [n=3]). Infections and infestations occurred in 55.2% of glofitamab-exposed patients, with COVID-19 the most common infection (16.3%), occurring during the COVID-19 pandemic. Immune recovery was observed, with median B-cell and immunoglobulin M counts above the lower limit of normal 18–24 months after EOT. Glofit-GemOx treatment did not negatively affect T-cell levels. Conclusion After 3 years of follow-up, sustained benefits with Glofit-GemOx treatment were observed, demonstrating superior OS, PFS, and CR rates compared with R-GemOx in ASCT-ineligible patients with R/R DLBCL. Most patients that reached CR remained progression free and alive 2 years after EOT. A more pronounced efficacy benefit was observed for Glofit-GemOx versus R-GemOx in patients with 1 prior LOT. The safety profile remained consistent with the known risks of each study drug and was manageable. This updated analysis demonstrates the sustained remission and continued survival advantages that fixed-duration Glofit-GemOx offers for patients with R/R DLBCL.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
爱笑美女完成签到,获得积分10
11秒前
犹豫擎苍完成签到,获得积分10
11秒前
null的应助被科研通管家采纳,获得10
13秒前
null的应助被科研通管家采纳,获得10
13秒前
29秒前
madeleinli的应助被纯情的阁采纳,获得10
43秒前
慕青的应助被纯情的阁采纳,获得10
43秒前
madeleinli的应助被纯情的阁采纳,获得10
44秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
44秒前
44秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
44秒前
小蘑菇的应助被纯情的阁采纳,获得10
44秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
45秒前
科研通AI6.2的应助被纯情的阁采纳,获得10
45秒前
45秒前
单纯冰菱完成签到,获得积分10
47秒前
54秒前
火星上的山柳完成签到,获得积分10
56秒前
59秒前
大个的应助被Eva小飞鱼采纳,获得10
1分钟前
称心的忆山完成签到,获得积分10
1分钟前
1分钟前
agathahqs的应助被纯情的阁采纳,获得30
1分钟前
agathahqs的应助被纯情的阁采纳,获得10
1分钟前
agathahqs的应助被纯情的阁采纳,获得10
1分钟前
agathahqs的应助被纯情的阁采纳,获得10
1分钟前
null的应助被纯情的阁采纳,获得10
1分钟前
null的应助被纯情的阁采纳,获得10
1分钟前
奔跑的应助被纯情的阁采纳,获得10
1分钟前
1分钟前
冷傲的中恶完成签到,获得积分10
1分钟前
敏感兰完成签到,获得积分10
1分钟前
double_sweet完成签到,获得积分10
2分钟前
Benhnhk21完成签到,获得积分10
2分钟前
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
顾矜的应助被纯情的阁采纳,获得10
2分钟前
完美的飞兰完成签到,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158827
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748395
什么是DOI,文献DOI怎么找? 3427099
关于科研通互助平台的介绍 2552000
邀请新用户注册赠送积分活动 2471370